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Abstract The etiology of Parkinson’s disease (PD) may
involve endogenous and exogenous factors. 1-Benzyl-1,2,3,4-
tetrahydroisoquinoline (1BnTIQ), which was shown to be
neurotoxic for dopaminergic neurons, is one of such factors,
thus it can be used to construct an animal model of PD. In
contrast, 1,2,3,4-tetrahydroisoquinoline (TIQ) and 1-methyl-
1,2,3,4-tetrahydroisoquinoline (1MeTIQ) produce neuropro-
tective effects acting as monoamino oxidase (MAO) inhibi-
tors and free radical scavengers that reduce oxidative stress in
the mammalian brain. In this study, we aimed to investigate
the effects of neuroprotective compounds, TIQ and 1MeTIQ,
on the dopamine release in vivo in an animal model of PD
induced by chronic administration of 1BnTIQ (25 mg/kg
i.p.). Using an in vivo microdialysis methodology, we mea-
sured the impact of both acute and chronic treatment with
TIQ and 1MeTIQ (50 mg/kg i.p.) on 1BnTIQ-induced
changes in dopamine release in the rat striatum. Additionally,
the behavioral test was carried out to check the influence of
repeated administrations of the investigated compounds on
the locomotor activity of rats. The behavioral studies showed
that the chronic administration of 1BnTIQ produced a sig-
nificant elevation of exploratory locomotor activity, and both
the investigated amines, TIQ and 1MeTIQ, administered
together with 1BnTIQ completely prevented 1BnTIQ-pro-
duced hyperactivity. The in vivo microdialysis studies
demonstrated that the chronic treatment with 1BnTIQ caused
a significant and long-lasting increase in the dopamine release
(approximately 300 %) to the extracellular space in the rat
striatum, which was demonstrated in the basal samples 24 h
after 1BnTIQ injection. The combined chronic administration
of 1BnTIQ and the investigated compounds, TIQ or 1MeTIQ,
completely antagonized the 1BnTIQ-induced essential dis-
turbances of the dopamine releasing to the extracellular space
in the striatum. In conclusion, we suggest that higher con-
centrations of 1BnTIQ in the brain produced distinct
impairment in the dopamine release, whereas TIQ and
1MeTIQ (compounds with previously revealed neuroprotec-
tive properties) completely prevented 1BnTIQ-induced
abnormalities in the function of dopamine neurons and
restored the dopamine release to the control values.
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Introduction
Tetrahydroisoquinolines are a group of endogenous com-
pounds that are present in the mammalian brain (Abe et al.
2005; Yamakawa et al. 1999; Yamakawa and Ohta
1997, 1999). Some of these compounds, such as 1-benzyl-
1,2,3,4-tetrahydroisoquinoline (1BnTIQ), have shown
neurotoxic properties and are considered to be involved in
the pathogenesis of Parkinson’s disease (PD) (Abe et al.
2001a; Kotake et al. 1995). Kotake et al. (1995) indicated
that the concentration of 1BnTIQ in the cerebrospinal fluid
(CSF) of parkinsonian patients was three times higher than
that in the CSF of the control group. Previous studies
revealed that chronic treatment with 1BnTIQ induces
parkinsonian-like symptoms in mammals (Kotake et al.
1995, 2003, 2010). 1BnTIQ accumulates in dopaminergic
neurons and can lead to parkinsonian symptoms. 1BnTIQ
evoked strong activation of the oxidative MAO-dependent
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catabolic pathway (Wa˛sik et al. 2009). In addition, 1BnTIQ
significantly inhibits the COMT-dependent O-methylation
pathway. This mechanism of action leads to an increase in
dopamine oxidation, and as a consequence, leads to an
increase in reactive oxygen species (ROS) formation in
dopaminergic neurons. Moreover, in vitro studies revealed
that 1BnTIQ induces cell death via apoptosis and produces
an increase in the formation of the active caspase-3 protein
fragments (Shavali and Ebadi 2003). These data suggest
that multiple administrations of 1BnTIQ might serve as an
adequate animal model of the progressive process of PD. In
contrast, 1,2,3,4-tetrahydroisoquinoline (TIQ), and espe-
cially its methyl derivative, 1-methyl-1,2,3,4-tetrahy-
droisoquinoline (1MeTIQ), have shown neuroprotective
effects in the brain (Abe et al. 2001b; Antkiewicz-Micha-
luk et al. 2003, 2004, 2006; Wa˛sik et al. 2016). TIQ and
1MeTIQ are reversible MAO inhibitors that strongly block
the MAO-dependent oxidative pathway and simultaneously
increase the COMT-dependent O-methylation catabolic
pathway. Therefore, both substances possess antioxidant
properties. These compounds inhibit free radical formation
and abolish H2O2 generation from dopamine via the Fenton
reaction (Singer and Ramsay 1995; Antkiewicz-Michaluk
et al. 2006; Patsenka and Antkiewicz-Michaluk 2004).
Additionally, 1MeTIQ acts as a natural scavenger of free
radicals. From a clinical point of view, the lack of a tol-
erance for its neuroprotective action after chronic treatment
is both interesting and important (Antkiewicz-Michaluk
et al. 2001; Wa˛sik et al. 2016).
To continue our previous studies, we would like to
investigate the effects of TIQ and 1MeTIQ, as earlier
demonstrated neuroprotective compounds, on the dopa-
mine release in vivo in an animal model of PD induced by
chronic administration of 1BnTIQ. Using in vivo micro-
dialysis methodology, we measured the impact of acute and
chronic treatment with TIQ and 1MeTIQ on 1BnTIQ-in-
duced disorders of dopamine release in the rat striatum. In
addition to the biochemical research, the behavioral test
was carried out to check the influence of repeated admin-
istration of 1BnTIQ on the motor activity of rats.
Materials and Methods
Animals and Treatments
All experiments were carried out in male Wistar rats with
an initial body weight of 280–300 g. All animals had free
access to the standard laboratory food and tap water and
were kept at room temperature (22C) under an artificial
light/dark cycle (12/12 h, light on at 7:00). The rats used
for the microdialysis study after surgery were housed for
several days individually. The experiments were carried
out between 09:00 and 16:00 h. Control rats were treated
with an appropriate solvent (0.9 % NaCl).
1BnTIQ was administered at a dose of 25 mg/kg
intraperitoneally (i.p.) and chronically for 14 consecutive
days. In the mixed group, TIQ or 1MeTIQ (50 mg/kg i.p.)
was administered once 20 min before the last 1BnTIQ
administration or was administered chronically 20 min
before each 1BnTIQ injection.
All experimental procedures were performed in accor-
dance with the National Institutes of Health Guide for the
Care and Use of Laboratory Animals and were approved by
the Bioethics Commission as compliant with the Polish
Law. All experimental procedures were approved by the
Local Bioethics Commission of the Institute of Pharma-
cology, Polish Academy of Sciences in Krako´w.
Drugs
1BnTIQ and 1MeTIQ were synthesized (according to Cannon
and Webster 1958) at the Department of Drug Chemistry of
the Institute of Pharmacology, the Polish Academy of Sci-
ences in Krakow. The purity of the compounds was verified
by measuring the melting point, and the homogeneity was
assessed on a chromatographic column. TIQ (Sigma-Aldrich,
USA) was obtained commercially. The compounds were
dissolved in a 0.9 % NaCl solution.
Behavioral Study
Locomotor Activity
Locomotor activity was assessed in actometers (Opto-Var-
imex activity monitors; Columbus Inst., USA) linked on-line
to a compatible IBM PC. Each cage (43 9 44 9 25 cm)
perimeter was lined with an array of 15 9 15 photocell
beams located 3 cm from the floor. Interruptions of the
photocell beams were counted as a measure of horizontal
locomotor activity which was defined as the distance traveled
(in cm). Rats were given 25 mg/kg 1BnTIQ i.p. as their last
dose (14-day chronic treatment group). In the combined
groups, TIQ or 1MeTIQ (50 mg/kg i.p.) was given chroni-
cally 20 min before each 1BnTIQ administration. Subse-
quently, the animals were transferred to experimental cages,
and locomotor activity (horizontal activity, traveled distance
in cm) was recorded for 90 min and analyzed using the Auto-
Track Software Program (Columbus Instruments, USA). Each
group comprised seven animals.
In Vivo Microdialysis
Rats were anesthetized with ketamine (75 mg/kg) and
xylazine (10 mg/kg) and secured in a stereotaxic frame
(Stoelting, USA). Vertical microdialysis guide cannulas
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(Intracerebral Guide Cannula with stylet; BAS Bioanalyt-
ical, USA) were implanted in the striatum (STR) according
to the following stereotaxic coordinates: A/P ?1.0, L/M
?2.5, and V/D -3.5 mm from bregma and the dura (G.
Paxinos and C.H. Watson). Fourteen days after surgery,
microdialysis probes were inserted into the cannulas, and
the striatum was perfused with an artificial cerebrospinal
fluid (aCSF), which consisted of 140 mM NaCl, 2.7 mM
KCl, 1.2 mM CaCl2, 1 mM MgCl2, 0.3 mM NaH2PO4, and
1.7 mM Na2HPO4 (pH 7.4), at a flow rate of 1.5 ll/min
with a microinfusion pump (Stoelting, Illinois USA).
Samples were collected from freely moving rats in 20-min
intervals after a 3-h wash-out period. 1BnTIQ was injected
chronically (for 14 consecutive days) in a 25 mg/kg i.p.,
and dialysis samples were collected for 180 min. In the
mixed groups, 1MeTIQ or TIQ (50 mg/kg i.p.) was
administered 20 min before the last dose of 1BnTIQ
(acute) or 20 min before each 1BnTIQ injection (chronic).
All dialysates were immediately frozen on the dry ice (-70
oC), until they were used in a biochemical assay.
Levels of dopamine (DA) and its extraneuronal
metabolite, 3-methoxytyramine (3-MT), were assayed in
dialysates (20 ll) using HPLC with electrochemical
detection as described below. The chromatograph Dionex
Ultimate 3000 (Coulochem III, Germany) was equipped
with C18 columns (Hypersil Gold; 150 mm 9 3l). The
mobile phase comprised 0.05 M citrate–phosphate buffer
(pH 3.5), 0.1 mM EDTA, 1 mM sodium octyl sulfonate,
and 3.5 % methanol. The flow rate was maintained at
0.75 ml/min. Chromatographic data were processed using
the Chromeleon Dionex computer programme (Germany).
Dopamine and its metabolites were quantified by chro-
matograph peak height and compared with standards run
on the day of the analysis. At the end of the experiment,
frozen brains were examined histologically for correct
probe placement. Each group consisted of six animals.
Calculations and Statistics
Data obtained from the locomotor activity and microdial-
ysis studies were analyzed by a two-way analysis of vari-
ance (ANOVA) for repeated measures, followed by
Duncan’s post hoc test, if significant differences were
detected.
Results
The Effect of Chronic Administration of TIQ
on 1BnTIQ-Induced Hyperactivity in Rats
The multiple 1BnTIQ (25 mg/kg i.p.) administrations
produced a significant increase in the horizontal locomotor
activity of rats (F[1,24] = 16.30; p\ 0.01), while chronic
administration of TIQ (50 mg/kg i.p.) induced a significant
reduction in the locomotor activity of rats (F[1,24] =
18.29; p\ 0.01). In the combined group, TIQ completely
antagonized 1BnTIQ-induced hyperactivity (Fig. 1a).
The Effect of Chronic 1MeTIQ Administration
on 1BnTIQ-Induced Hyperactivity in Rats
As shown in Fig. 1b, the multiple (14-day) administrations
of 1BnTIQ at a low dose of 25 mg/kg (i.p.) significantly
increased (F[1,24] = 9.17; p\ 0.01) the locomotor activ-
ity, while the chronic administration of 1MeTIQ (50 mg/kg
i.p.) over 14 days induced a significant (F[1,24] = 10.65;
p\ 0.01) decrease in this parameter. In the joint
1BnTIQ ? 1MeTIQ treatment group, rats showed the
response similar to that for TIQ, i.e., 1MeTIQ completely
antagonized the 1BnTIQ-induced hyperactivity (Fig. 1b).
The Effect of Chronic 1BnTIQ Administration on
the dopamine release in vivo
The mean control basal extracellular concentration of
dopamine in dialysates obtained from the striatum was
approximately 17.8 ± 2.3 (pg/20 ll). A statistical analysis
demonstrated a significant increase (aprox. 300 %;
F[1,17] = 16.54; p\ 0.01) in dopamine concentration in
the synaptic cleft in the basal samples (from -60 to 0 min.)
24 h after chronic 1BnTIQ (25 mg/kg i.p.) administration.
The last dose of 1BnTIQ fortified this effect approximately
200 %, and after 60 min, the concentration of dopamine
returned to the value which was observed in the basal
samples but it still was elevated about 300 % in compar-
ison with the control group (saline) (Figs. 2a, b, 4a, b).
The Effect of a Single or Chronic Administration
of TIQ on 1BnTIQ-Induced Changes
on the Dopamine Release in the Rat Striatum
After acute TIQ administration, an increase in the dopa-
mine release was observed (approximately 300 %)
(Fig. 2a). A post hoc analysis demonstrated that chronic
1BnTIQ administration, co-administered with acute TIQ,
showed a significant increase in dopamine release in the
striatum of approximately 300 % (F[1,16] = 18.18;
p\ 0.01) of the basal samples (Fig. 2a). However, after
the last dose of 1BnTIQ and TIQ, the dopamine release
increased up to 400 % within a short period (Fig. 2a).
In contrast to the effect of chronic 1BnTIQ, chronic
administration of TIQ did not change the extracellular
dopamine concentration estimated 24 h after the last
injection (the basal samples; F[1,16] = 0.47; N.S.), but it
increased the dopamine release after the last dose of TIQ
650 Neurotox Res (2016) 30:648–657
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(up to 500 %) (Fig. 2b). Interestingly, in the combined
treatment group, chronic administration of TIQ com-
pletely blocked the effect induced by multiple admin-
istrations of 1BnTIQ (Fig. 2b). The dopamine
concentration in the basal samples was similar to that in
the control (saline group); however, after the last
injection of TIQ and 1BnTIQ, the dopamine release was
increased by approximately 300 % (F[1,16] = 15.38;
p\ 0.01) (Figs. 2b).
The Effect of a Single or Chronic Administration
of TIQ on 1BnTIQ-Induced Changes
on the Concentration of 3-MT in the Rat Striatum
As shown in Fig. 3a, acute TIQ (50 mg/kg i.p.) adminis-
tration produced a significant (F[1,16] = 19.14; p\ 0.05)
increase in the concentration of 3-MT in the rat striatum
(up to 450 %). This effect was strongly potentiated in the
combined treatment group (chronic 1BnTIQ ? acute TIQ),
(the concentration of 3-MT was elevated approximately
2500 %; F[1,16] = 11.84; p\ 0.01) (Fig. 3a).
The post hoc analysis indicated that chronic TIQ
(50 mg/kg i.p.) administration produced a huge and sig-
nificant (F[1,16] = 37.61; p\ 0.01) increase in the con-
centration of 3-MT in the rat striatum (up to 3500 %)
(Fig. 3b). In the combined treatment group (with chronic
treatment TIQ and 1BnTIQ), this effect was weaker, and
the concentration of 3-MT was elevated up to 2500 %
(F[1,16] = 30.94; p\ 0.01) (Fig. 3b).
The Effect of a Single or Chronic Administration
of 1MeTIQ on 1BnTIQ-induced Changes
in the Dopamine Release in the Rat Striatum
An acute dose of 1MeTIQ produced an increase in the
release of dopamine up to 200 % (Fig. 4a). Duncan’s test
indicated that chronic 1BnTIQ ? acute 1MeTIQ treatment
induced a significant increase in the dopamine release in
the rat striatum approximately 300 % (F[1,17] = 10.94;
p\ 0.01) of the basal samples (Fig. 4a). However, after
the last dose of 1BnTIQ combined with an acute dose of
1MeTIQ, we observed a reduction in the release of dopa-
mine to 200 % of the basal samples (Fig. 4a).
Fig. 1 The effect of chronic
administration of TIQ (a) or
1MeTIQ (b) on 1BnTIQ-
induced hyperactivity in rats.
Rats received a single injection
of saline (control). 1BnTIQ was
administered at a dose of
25 mg/kg i.p. chronically for 14
consecutive days. In the mixed
group, TIQ (a) or 1MeTIQ
(b) (50 mg/kg i.p.) was
chronically administered
20 min before each 1BnTIQ
injection. Rats were placed into
actometers immediately after
the treatment. Movements were
recorded for 45 min. The data
are expressed as the
mean ± SEM (n = 6 animals).
The data were analyzed with a
two-way repeated measures
ANOVA, followed by Duncan’s
post hoc test. Statistical
significance: *p\ 0.05,
**p\ 0.01 versus saline-treated
group; ?p\ 0.05, ??p\ 0.01
versus 1BnTIQ-treated group
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Chronic treatment with 1MeTIQ did not change the
dopamine level in basal samples; however, a weak increase
in dopamine release after the last dose of 1MeTIQ (up to
200 %; F[1,16] = 1.63; N.S.) was observed (Fig. 4b).
Interestingly, in the combined treatment group, chronic
injection of 1MeTIQ completely blocked the effect induced
by repeated administrations of 1BnTIQ (Fig. 4b). The
concentration of dopamine in basal samples was slightly
above the control (saline) group, and after the final injec-
tion of 1MeTIQ and 1BnTIQ, the dopamine release
increased by approximately 200 % (Fig. 4b).
The Effect of Chronic 1BnTIQ Administration on
3-MT release in vivo
Duncan’s test indicated that chronic 1BnTIQ administra-
tion did not change the level of 3-MT (Figs. 3a, b, 5a, b).
The Effect of a Single or Chronic Administration
of 1MeTIQ on 1BnTIQ-Induced Changes
on the Concentration of 3-MT in the Rat Striatum
As shown in Fig. 5a, acute 1MeTIQ (50 mg/kg i.p.)
administration produced a significant (F[1,17] = 30.86;
p\ 0.05) increase in the concentration of 3-MT in the rat
striatum (up to 500 %). This effect was strongly potenti-
ated in the joint treatment group when 1MeTIQ was given
with the last dose of 1BnTIQ (the concentration of 3-MT
was elevated approximately 2000 %; F[1,17] = 14.03;
p\ 0.01) (Fig. 5a).
In contrast to the effect of chronic treatment with
1BnTIQ, multiple 1MeTIQ (50 mg/kg i.p.) administrations
produced a huge and significant (F[1,17] = 52.41;
p\ 0.01) increase in the concentration of 3-MT in the rat
striatum (up to 2000 %) (Fig. 5b). A similar effect was
observed in the mixed group (with chronic treatment
Fig. 2 The effect of acute
(a) or chronic (b) administration
of TIQ on 1BnTIQ-induced
changes on dopamine release in
the rat striatum, 1BnTIQ was
administered chronically
(1BnTIQch) at a dose of 25 mg/
kg i.p. for 14 consecutive days.
In the mixed group, TIQ
(50 mg/kg i.p.) was given
acutely (TIQa) a 20 min before
the last 1BnTIQ administration
or chronically (TIQch),
b 20 min before each 1BnTIQ
administration. The control
group was treated with saline.
The dialysate was collected
every 20 min. The
concentration of dopamine
(DA) was measured. The data
are expressed as the
mean ± SEM (n = 5–6).
Statistical significance:
*p\ 0.05, **p\ 0.01 from the
basal value; ?p\ 0.05 versus
1BnTIQ-treated group
(Duncan’s test)
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1MeTIQ and 1BnTIQ), and the concentration of 3-MT was
increased up to 2000 % (F[1,17] = 47.15; p\ 0.01)
(Fig. 5b).
Discussion
The chronic administration of 1BnTIQ produced clear and
significant disturbances in the function of dopaminergic
neurons, which led to an increase in dopamine release in
the striatum. Based on our previous experiments, we con-
firmed that chronic treatment with a low dose of 1BnTIQ
(25 mg/kg i.p.) damaged the dopamine storage mecha-
nisms causing its non-physiological rise in the extracellular
space in the rat striatum (Wa˛sik et al. 2009, 2014). The
main finding of the present study is that chronic adminis-
tration of TIQ and 1MeTIQ completely prevented the
disorders on dopamine release induced by multiple
administrations of 1BnTIQ. Dopamine, the main neuro-
transmitter involved in motor control and Parkinson’s
disease, is metabolized both intra- and extraneuronally.
The extraneuronal dopamine metabolite, 3-MT, which is
present in the synaptic cleft at relatively low concentrations
comparable to dopamine, is considered to be a marker of
dopamine release (Karoum et al. 1994). However, in con-
trast to intraneuronal dopamine metabolite, DOPAC and
the final metabolite HVA, 3-MT may be biologically
active. It was demonstrated previously that 3-MT has a
considerable affinity as antagonist for noradrenergic a1 and
dopamine D1 and D2 receptors in rat brain (Antkiewicz-
Michaluk et al. 2008). In the behavioral tests chronic
administration of 1BnTIQ-induced hyperactivity, while
multiple injection of both, TIQ and 1MeTIQ significantly
decreased the rats locomotor activity (Fig. 1a, b). Addi-
tionally, in the combined groups, TIQ and 1MeTIQ
inhibited 1-BnTIQ-induced hyperactivity. In that light, the
mechanism of the action of TIQ and 1MeTIQ, leading to an
increase the concentration of 3-MT antagonism to
1BnTIQ-produced hyperactivity may be explained by its
inhibition to catecholaminergic receptors.
Although all substances used in the present study belong
to the same chemical group, their mechanisms of action are
completely opposite. 1BnTIQ activates the dopamine oxi-
dation pathway, which leads to the elevation in free radical
Fig. 3 The effect of acute
(a) or chronic (b) administration
of TIQ on 1BnTIQ-induced
changes in 3-MT concentration
in the rat striatum, 1BnTIQ was
administered chronically
(1BnTIQch) at a dose of 25 mg/
kg i.p. for 14 consecutive days.
In the mixed group, TIQ
(50 mg/kg i.p.) was given
acutely (TIQa) a 20 min before
the last 1BnTIQ administration
or chronically (TIQch),
b 20 min before each 1BnTIQ
administration. The control
group was treated with saline.
The dialysate was collected
every 20 min. The
concentration of extraneuronal
metabolite of dopamine 3-MT
was measured. The data are
expressed as the mean ± SEM
(n = 5–6). Statistical
significance: *p\ 0.05,
**p\ 0.01 from the basal
value; ?p\ 0.05 versus
1BnTIQ-treated group
(Duncan’s test)
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production (Wa˛sik et al. 2014). On the other hand, TIQ and
1MeTIQ exhibit a contrasting molecular mechanism, and
act as reversible MAO inhibitors, blocking the production
of free radicals and activating the COMT-dependent
O-methylation pathway (Antkiewicz-Michaluk et al. 2001;
Wa˛sik et al. 2009). Our present in vivo study demonstrated
that multiple administrations of 1BnTIQ produced a sig-
nificant and long-lasting increase (approximately 300 % in
comparison to the saline group) in dopamine release in the
rat striatum, measured in the basal samples 24 h after its
13th injection (1 h before the last 14th injection). Such
permanent increase in dopamine levels in the extracellular
space after the chronic administrations of 1BnTIQ may,
like the treatment with psychostimulants, leads to neuro-
toxic effects. After the 14th (last) dose of 1BnTIQ, dopa-
mine release was elevated up to 500 % of the saline group;
however, at the same time, no change in 3-MT concen-
tration was observed. Moreover, 3-MT is considered as the
most reliable indicator of dopamine release into the
synaptic cleft (Egan et al. 1991; Karoum et al. 1994).
Additionally, as demonstrated previously, 3-MT, in con-
trast to DOPAC and HVA, is an active metabolite of
dopamine and possesses its own receptor activity (An-
tkiewicz-Michaluk et al. 2008; Alachkar et al. 2010). It is
well known that elevation of dopamine release induces an
increase of dopaminergic activity and leads to hyperac-
tivity. The results of the in vivo microdialysis study are in
agreement with the behavioral locomotor activity test in
which chronic treatment with 1BnTIQ-produced hyperac-
tivity in rats (Fig. 1a, b).
As we demonstrated earlier, 1BnTIQ similarly to
reserpine (a specific vesicular monoamine transporter 2
(VMAT2) inhibitor) significantly depleted striatal dopa-
mine (Wa˛sik et al. 2009). We postulated that 1BnTIQ
might damage VMAT2 in dopaminergic neurons, leading
to the pathological release of dopamine into the cytosol,
and increased its MAO-dependent oxidation and free rad-
ical production (Wa˛sik et al. 2014). On the other hand,
1BnTIQ in low micromolar concentrations significantly
inhibited the dopamine reuptake in slices of the rat striatum
(Patsenka et al. 2004). Similarly, Okada et al. (1998)
demonstrated that 1BnTIQ inhibited the uptake of [3H]-
dopamine by the dopamine transporter expressed in
HEK293 cells. We suggest that DAT is responsible for the
Fig. 4 The effect of acute
(a) or chronic (b) administration
of 1MeTIQ on 1BnTIQ-induced
changes in dopamine release in
the rat striatum, 1BnTIQ was
administered chronically
(1BnTIQch) at a dose of 25 mg/
kg i.p. for 14 consecutive days.
In the mixed group, 1MeTIQ
(50 mg/kg i.p.) was given
acutely (1MeTIQa) a 20 min
before the last 1BnTIQ
administration or chronically
(1MeTIQch), b 20 min before
each 1BnTIQ administration.
The control group was treated
with saline. The dialysate was
collected every 20 min. The
concentration of dopamine
(DA) was measured. The data
are expressed as the
mean ± SEM (n = 5–6).
Statistical significance:
*p\ 0.05, **p\ 0.01 from the
basal value; ?p\ 0.05 versus
1BnTIQ-treated group
(Duncan’s test)
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selective transport of 1BnTIQ into the dopaminergic neu-
rons, leading to the 1BnTIQ neurotoxicity correlated with
impaired dopamine storage via inhibition of VMAT2
(Wa˛sik et al. 2009). Since TIQ and 1MeTIQ have also
affinity to DAT, both substances may restrict access of
1BnTIQ to the DAT (Patsenka et al. 2004). This mecha-
nism results in a reduction of penetration of 1BnTIQ into
the neurons. The present study revealed that acute treat-
ment with TIQ induced an increase in dopamine release
(approximately 300 %), while 1MeTIQ showed a similar
effect of a lesser magnitude (Figs. 2a, 4a). Taking into
account that both investigated compounds, TIQ and
1MeTIQ, act as reversible MAO inhibitors, they shift
dopamine catabolism toward the COMT-dependent
O-methylation pathway, which leads to a significant
increase in the extraneuronal concentration of the dopa-
mine metabolite 3-MT (Antkiewicz-Michaluk et al. 2001;
Patsenka and Antkiewicz-Michaluk 2004). In the present
paper, such properties of TIQ and 1MeTIQ were confirmed
in our in vivo microdialysis studies which demonstrated an
increase in 3-MT level by approximately 500 % in the case
of acute administration and up to 2500 % versus saline
group after chronic treatment. It is worth emphasizing, as
previously demonstrated that 3-MT, an extraneuronal
dopamine metabolite, shows affinity for a1-adrenergic and
D1 and D2 receptors as an antagonist, and may play an
important role as an inhibitory regulator, counteracting the
excessive stimulation of catecholaminergic neurons (An-
tkiewicz-Michaluk et al. 2008; Alachkar et al. 2010). Thus,
a high concentration of 3-MT may play an important role in
locomotor activity as dopamine D2 and noradrenergic a1
receptors antagonists (Antkiewicz-Michaluk et al. 2008).
Such mechanism of action of 3-MT leads to the paradox-
ical effect, where despite the increase in dopamine release,
we observed decrease in the locomotor activity in rats after
treatment with both, TIQ and 1MeTIQ (Fig. 1a, b).
In the combined treatment group, an acute dose of TIQ
given before the last dose of 1BnTIQ only slightly reduced
the effect of 1BnTIQ, whereas acute administration of
1MeTIQ produced a clear decrease in dopamine release
(Figs. 2a, 4a). In both combined treatment groups, a mas-
sive increase in 3-MT levels was observed (2500 and
2000 %, respectively; Figs. 3a, 5a). Such an increase in the
3-MT concentration may be associated with the retention
of dopamine in the extracellular space, due to dopamine
reuptake blockade by TIQ and 1MeTIQ, and catabolism of
Fig. 5 The effect of acute
(a) or chronic (b) administration
of 1MeTIQ on 1BnTIQ-induced
changes in 3-MT concentration
in the rat striatum, 1BnTIQ was
administered chronically
(1BnTIQch) at a dose 25 mg/kg
i.p. for 14 consecutive days. In
the mixed group, 1MeTIQ
(50 mg/kg i.p.) was given
acutely (1MeTIQa) a 20 min
before last 1BnTIQ
administration or chronically
(1MeTIQch), b 20 min before
each 1BnTIQ administration.
The control group was treated
with saline. The dialysate was
collected every 20 min. The
concentration of extraneuronal
metabolite of dopamine 3-MT
was measured. The data are
expressed as the mean ± SEM
(n = 5–6). Statistical
significance: *p\ 0.05,
**p\ 0.01 from the basal
value; ?p\ 0.05 versus
1BnTIQ-treated group
(Duncan’s test)
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all available dopamine by the COMT-dependent
O-methylation pathway. It is worth emphasizing that such a
mechanism of action for TIQ and 1MeTIQ inhibits the
production of free radicals, which are formed during the
catabolism of dopamine by MAO-dependent oxidation, and
consequently leads to a reduction in oxidative stress (An-
tkiewicz-Michaluk et al. 2006; Miller et al. 1996; Patsenka
and Antkiewicz-Michaluk 2004).
Interestingly, in both combined treatment groups,
chronic treatment with TIQ or 1MeTIQ completely
antagonized the 1BnTIQ-induced pathological increase in
dopamine release in the basal samples (Figs. 2b, 4b).
Simultaneously, in these groups, we observed a huge ele-
vation in the concentration of 3-MT after the last dose of
TIQ and 1MeTIQ (up to 2500 and 2000 %, respectively)
(Figs. 3b, 5b). These results are important because they
demonstrate that chronic administration of both TIQ and
1MeTIQ can counteract the disturbances in dopamine
release produced by multiple administrations of 1BnTIQ.
We suggest that TIQ and 1MeTIQ given before each
1BnTIQ injection inhibit DAT and in this way block
penetration of 1BnTIQ into the neurons. Since 1BnTIQ
penetrates into cells via DAT, DAT is inhibited by prior
injection of TIQ and 1MeTIQ; therefore, in the combined
treatment groups, we did not observe the effect of 1BnTIQ
(Patsenka et al. 2004). The data from the behavioral tests
(locomotor activity) confirmed that a high concentration of
3-MT, which was observed in both joint treatment groups,
acted as an endogenous neuroleptic, as previously
demonstrated (Antkiewicz-Michaluk et al. 2008), and
could block hyperactivity in rats (Fig. 1a, b). It is important
to mention that pronounced increases in dopamine
O-methylation in the COMT-dependent pathway may
provide neuroprotection (Antkiewicz-Michaluk et al. 2001;
Miller et al. 1996). It was also indicated that elevation of
3-MT in the process of dopamine O-methylation protected
cells against oxidative stress (Miller et al. 1996). The
neuroprotective properties of 1MeTIQ against different
dopaminergic neurotoxins, including MPTP, 6-OHDA,
rotenone, and 1BnTIQ, were also demonstrated in in vitro
studies in cultured mesencephalic neurons (Kotake et al.
2005) and in ex vivo studies (Antkiewicz-Michaluk et al.
2011; Wa˛sik et al. 2016).
Conclusions
Summing up the results, based on the in vivo microdialysis
study presented in this paper, we suggest that both
endogenous amines TIQ and 1MeTIQ can antagonize
1BnTIQ-induced clear disorders of dopamine release
in vivo in rat striatum. Furthermore, these amines were able
to restore the physiological functions of striatal dopamine
neurons disturbed by chronic application of 1BnTIQ.
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